A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
about
A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Adrenal Diagnostics: An Endocrinologist's Perspective focused on HyperaldosteronismIs there a new dawn for selective mineralocorticoid receptor antagonism?Beneficial effects of proanthocyanidins in the cardiac alterations induced by aldosterone in rat heart through mineralocorticoid receptor blockadeA comprehensive review of an unmet public health issue: resistant hypertension.Interfering with mineralocorticoid receptor activation: the past, present, and futureA small molecule screening to detect potential therapeutic targets in human podocytes.Suppression of aldosterone synthesis and secretion by ca(2+) channel antagonists.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Efficacies of Controlling Morning Blood Pressure and Protecting the Kidneys by Treatment With Valsartan and Nifedipine CR or Valsartan and Amlodipine (MONICA Study)Primary aldosteronism, diagnosis and treatment in Japan.A comprehensive review of the clinical aspects of primary aldosteronism.Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.Key advances in antihypertensive treatment.1,4-dihydropyridines: the multiple personalities of a blockbuster drug family.Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.Are there any new pharmacologic therapies on the horizon to better treat hypertension? A state-of-the-art paper.Management of hypertension and heart failure in patients with Addison's disease.Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.Secondary Hypertension in Pregnancy.Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.Clinical roles of calcium channel blockers in ischemic heart diseases.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.Ca(2+) channel blocker benidipine promotes coronary angiogenesis and reduces both left-ventricular diastolic stiffness and mortality in hypertensive rats.Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.[New therapy concepts for heart failure with preserved ejection fraction].L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney diseaseCalcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection
P2860
Q24604026-3BAD77B0-AEB7-4697-880D-81B060AFF9ECQ27006954-3EA7127B-2F23-4EB1-BC56-B69ACDF0BBDFQ27027792-4841B195-8B68-4E3B-ACF3-CB1C638E767BQ28544460-63E23136-77AC-4CA0-9C05-C153FF7201F7Q30235310-9D252638-4539-440B-AE77-3E33081C5006Q34019947-17F5545A-6651-47B0-A916-0F5523DA5CFFQ36168378-CDB62627-D381-4F12-B718-0EA4BD2C6CC2Q36336748-87B47193-0C60-4CE4-9502-9D7B142E34EEQ36437145-0F5CB83E-F865-4C1E-8CD0-A0442985FF45Q37255216-B56284EA-7B2A-435B-98BF-BA4AFE060476Q37855616-E8F6C67B-2067-4AB7-807A-10BF37E3B9FBQ37879448-693B4487-9F6F-4DFD-891B-07CA85453F21Q37939427-5A77306D-A470-4997-AF60-B78C7B6B9399Q37976974-B430C11F-1E33-4758-9D4D-40A4144287AAQ37995074-521FB01F-93B8-43DC-BD4C-2658CFFE839DQ38125687-312549ED-FB6D-4F38-BBB7-3FD4F6EC1E9DQ38181208-1D3177F9-F7F2-4106-A32B-DF8DB376489BQ38208808-D86D42F7-5601-4E65-8D98-2B477CED8223Q38241389-6A4F3A7C-D83F-4243-B4E3-3F7740367D24Q38383249-71A55E7A-6697-412B-B9B1-0E4C741793E3Q38525964-F2FFD3C7-869C-496F-B867-DD6CFA621EA1Q38658657-AAF37C3F-772D-41F1-A25E-0E91F62C51B4Q39103506-FF9D43F0-4EC3-4FE9-8801-02AD9BAFC649Q39199991-F07D5849-9497-4738-915A-B48C1338971AQ42709938-1D457F14-E7D0-4E1C-9DF3-C3A516F61802Q42716993-60768D08-54BE-4BB7-B985-F5B2A37F62AAQ45964954-897AA25E-2039-47E8-A5A3-A008FA066F0DQ51748655-D90F5C16-225E-4EF1-9B53-CAB4B8906A7DQ52869074-F1E7F92B-46AA-43E1-BA42-75F729A7F299Q54390737-49EC3296-A338-4BF5-AA7E-EA4162DA54AEQ57911462-48A15394-32EC-4F4A-8DA6-722D4492BBF2Q58725666-E188666C-CB31-4731-93F4-C8B01AA4F0D9
P2860
A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
A number of marketed dihydropy ...... receptor antagonist activity.
@en
type
label
A number of marketed dihydropy ...... receptor antagonist activity.
@en
prefLabel
A number of marketed dihydropy ...... receptor antagonist activity.
@en
P2093
P1433
P1476
A number of marketed dihydropy ...... receptor antagonist activity.
@en
P2093
Charles W Bolten
Chunsheng Xia
James R Blinn
Jessica D Dietz
John W Funder
Maria A Payne
P304
P356
10.1161/HYPERTENSIONAHA.107.103580
P407
P577
2008-02-04T00:00:00Z